GeneRADAR
Proprietary next-generation liquid biopsy platform for simultaneous DNA and RNA profiling
Platform · On PremiseCompany source
Company profile
About Predicine
Predicine Inc. is a precision medicine company specializing in next-generation liquid biopsy technology for cancer diagnostics and monitoring. The company's proprietary GeneRADAR platform enables simultaneous profiling of cell-free DNA and RNA from blood and urine samples, providing comprehensive molecular insights into cancer biology. Predicine offers a portfolio of CLIA-certified and CAP-accredited genomic profiling assays including PredicineATLAS (600-gene panel), PredicineCARE (200-gene cfDNA assay), PredicineRNA (88-gene fusion/splicing detection), PredicineHEME (259-gene hematologic malignancies panel), and PredicineBEACON (MRD detection). The company operates CLIA/CAP-certified laboratories in California and Shanghai, supporting biomarker-driven clinical trials for leading biopharmaceutical companies across the United States and China. Predicine's technology enables treatment selection, disease monitoring, minimal residual disease detection, and assessment of key biomarkers including TMB, MSI, HRD, and homologous recombination deficiency. The company pioneered urine-based liquid biopsy for genitourinary cancers, offering a truly non-invasive alternative to blood-based testing. Predicine serves biopharmaceutical partners conducting Phase I-III clinical trials, providing end-to-end biomarker solutions from target discovery through commercial launch.
Company description Predicine official website
Primary marketPrecision Medicine & Genomics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Predicine?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- B-cell malignancies
- Biliary tract cancer
- Bladder cancer
- Breast cancer
- Chronic lymphocytic leukemia (CLL)
- Genitourinary cancers
- Head and neck squamous cell carcinoma
- Hematologic malignancies
- Mantle cell lymphoma (MCL)
- Pan-cancer solid tumors
- Prostate cancer
- Small lymphocytic lymphoma (SLL)
Who it serves
- Academic research institutions
- Biopharmaceutical companies
- Clinical trial sponsors
- Oncology researchers
Deployment & integration
On Premise deployment with recorded integration context.
Geographic context
MarketsChina · United States
Company sourceOfficial website
Company milestones
Platform expansion
Published research on ctDNA biomarkers in giredestrant response for breast cancer, RAS-targeted therapy combinations, and tumor-informed ctDNA in HPV-independent head and neck cancer
Partnerships
Recorded partners
- International Society of Liquid Biopsy
- Leading biopharmaceutical companies (unnamed)
- Northwestern University (Massimo Cristofanilli, M.D.)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
PredicineATLAS™
600-gene NGS assay for comprehensive cancer variant profiling with TMB, MSI, HRD assessment
Platform · On PremiseCompany source
PredicineBEACON™
Next-generation actionable minimal residual disease (MRD) detection platform
Platform · On PremiseCompany source
PredicineCARE™
200-gene ultra-sensitive cfDNA assay for treatment selection from blood and urine
Platform · On PremiseCompany source
PredicineHEME™
259-gene NGS assay for hematologic malignancies including CLL/SLL and MCL
Platform · On PremiseCompany source
PredicineRNA™
88-gene cfRNA assay for detection of gene fusions and splicing variants
Platform · On PremiseCompany source
PredicineWES+™
Whole exome sequencing plus solution for comprehensive genomic analysis
Platform · On PremiseCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Inhibition of PGC1β-dependent mitochondrial biogenesis enhances EGFR-targeted therapy in lung cancer.EMBO molecular medicine · Jul 30, 2026
Clinicopathological and molecular study of two unique cases with microglandular and acinic cell-like breast carcinoma.Histopathology · Jun 16, 2026
Clinical and molecular correlates of circulating tumor fraction in patients with metastatic pancreatic ductal adenocarcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · May 26, 2026
Development, characterization, and inter-laboratory validation of methylated human cell free DNA candidate reference materials.Clinical epigenetics · May 18, 2026
Urinary Biomarkers Objectively Measure Minimal Residual Disease in Non-Muscle-Invasive Bladder Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · May 1, 2026
DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinoma.Nature communications · Mar 7, 2026
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Variant detection sensitivity
Reportable range down to 0.001% VAF for longitudinal monitoring
Sample input requirements
Robust profiling from as little as 0.4mL plasma or 1ng cfDNA
Urine detection performance
More robust variant detection in urine than blood for bladder cancer
Turnaround time
6-14 days depending on assay type
Biliary Tract Cancer Clinical Study
Longitudinal assessment of cfDNA to identify patients responding to immune checkpoint inhibitor therapy in biliary tract cancer
Deep reduction in variant allele frequency (VAF) among responders to immune checkpoint inhibitor therapy
Metastatic Prostate Cancer Study
Clinical and genomic insights into circulating tumor DNA-based alterations across metastatic hormone-sensitive and castrate-resistant prostate cancer
Comprehensive molecular insights into tumor biology to determine targeted therapy options
Northwestern University
Clinical application of liquid biopsy platform for precision medicine and patient care
Encouraging results supporting clinical application of liquid biopsy for patient care
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Massimo Cristofanilli
Strategic Advisor
06 · Company updates
Updates from Predicine
Recent articles published on Predicine's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Precision Medicine & Genomics
Companies using AI to analyze genomic, proteomic, metabolomic, or multi-omics data to provide personalized treatment recommendations, identify genetic risks, or develop targeted therapies. Includes genomic sequencing platforms with AI analysis, preventive medicine based on genetic risk assessment, and longevity care based on molecular and genetic data.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.